Skip to content

Aegerion Pharmaceuticals, Inc.: 10-Q filed 2011-11-14

What Aegerion Pharmaceuticals, Inc. reported in its quarterly report filed 2011-11-14 (fiscal Q3 2011): 34 published measures, 99 facts as tagged in accession 0001193125-11-311251.

This filing

Form
10-Q (quarterly report)
Filed
2011-11-14
Fiscal period
fiscal Q3 2011
Accession
0001193125-11-311251 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Aegerion Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-09-3084,757,814USD
At 2010-12-3145,747,112USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-09-3016,086,996USD
At 2010-12-314,668,698USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-09-3068,670,818USD
At 2010-12-3141,078,414USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-09-3036,089,532USD
At 2010-12-3144,100,897USD
At 2010-09-30407,884USD
At 2009-12-311,429,126USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-10,120,498USD92
2011-01-01 to 2011-09-30-25,557,674USD273
2005-02-04 to 2011-09-30-104,811,511USD2430
2010-07-01 to 2010-09-30-5,291,168USD92
2010-01-01 to 2010-09-30-8,285,796USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-21,426,808USD273
2005-02-04 to 2011-09-30-84,572,063USD2430
2010-01-01 to 2010-09-30-4,518,564USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-09-30256,861USD273
2005-02-04 to 2011-09-30360,767USD2430
2010-01-01 to 2010-09-307,234USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-09-3059,329,995USD273
2005-02-04 to 2011-09-30169,680,053USD2430
2010-01-01 to 2010-09-303,504,556USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-45,914,552USD273
2005-02-04 to 2011-09-30-49,018,458USD2430
2010-01-01 to 2010-09-30-7,234USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2011-09-30-116,546,460USD
At 2010-12-31-90,988,786USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2005-02-04 to 2011-09-30-1,793,129USD2430
2010-01-01 to 2010-09-30-1,793,129USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-09-30251,990USD
At 2010-12-3116,471USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-09-304,280,129USD273
2005-02-04 to 2011-09-3010,741,018USD2430
2010-01-01 to 2010-09-30713,238USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-10,561,738USD92
2011-01-01 to 2011-09-30-25,692,280USD273
2005-02-04 to 2011-09-30-100,104,579USD2430
2010-07-01 to 2010-09-30-2,863,602USD92
2010-01-01 to 2010-09-30-6,826,634USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-09-3083,571,324USD
At 2010-12-3144,605,641USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-07-01 to 2011-09-30334,692USD92
2011-01-01 to 2011-09-30779,022USD273
2005-02-04 to 2011-09-307,676,854USD2430
2010-07-01 to 2010-09-30607,462USD92
2010-01-01 to 2010-09-301,790,227USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-09-306,465,739USD
At 2010-12-314,668,698USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-09-301,003,260USD
At 2010-12-313,145,887USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2005-02-04 to 2011-09-30373USD2430

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-07-01 to 2011-09-3010,561,738USD92
2011-01-01 to 2011-09-3025,692,280USD273
2005-02-04 to 2011-09-30100,104,579USD2430
2010-07-01 to 2010-09-302,863,602USD92
2010-01-01 to 2010-09-306,826,634USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-07-01 to 2011-09-307,105,449USD92
2011-01-01 to 2011-09-3015,540,060USD273
2005-02-04 to 2011-09-3065,407,324USD2430
2010-07-01 to 2010-09-301,332,327USD92
2010-01-01 to 2010-09-303,625,379USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-09-3021,135,723shares
At 2010-12-3117,641,543shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-09-30185,240,501USD
At 2010-12-31131,549,805USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2011-09-30-44,089USD
At 2010-12-31590,759USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-09-30829,608USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-09-30871,259USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-09-30654,249USD
At 2010-12-31504,744USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2011-07-01 to 2011-09-30-10,120,498USD92
2011-01-01 to 2011-09-30-25,557,674USD273
2005-02-04 to 2011-09-30-128,474,924USD2430
2010-07-01 to 2010-09-30-6,172,314USD92
2010-01-01 to 2010-09-30-10,900,499USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-07-01 to 2011-09-303,456,289USD92
2011-01-01 to 2011-09-3010,152,220USD273
2005-02-04 to 2011-09-3034,697,255USD2430
2010-07-01 to 2010-09-301,531,275USD92
2010-01-01 to 2010-09-303,201,255USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2011-01-01 to 2011-09-3021,342USD273
2005-02-04 to 2011-09-30108,777USD2430
2010-01-01 to 2010-09-306,845USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2011-07-01 to 2011-09-30679,699USD92
2011-01-01 to 2011-09-30679,699USD273
2005-02-04 to 2011-09-30-1,773,572USD2430
2010-07-01 to 2010-09-30-1,835,322USD92
2010-01-01 to 2010-09-30-1,515,937USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2011-01-01 to 2011-09-30618,228USD273
2005-02-04 to 2011-09-303,326,439USD2430
2010-01-01 to 2010-09-30375,227USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-01-01 to 2011-09-3049,226,747USD273
2005-02-04 to 2011-09-30100,032,337USD2430

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-09-30-2,142,627USD273
2005-02-04 to 2011-09-30-9,306USD2430
2010-01-01 to 2010-09-301,566,233USD273

Inspect the source

Entity
Aegerion Pharmaceuticals, Inc. / CIK 0001338042
Captured
SEC response SHA-256
522c3af406e78cbef92d1883c63bfd97552757d1256ec392d9c3136363668fca

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001338042.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))